US 5,710,257 A · Method of causing selective immunosuppression using HL-60-related lectins

Abstract

Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds .beta.-galactoside-containing moieties independent of the presence or absence of Ca.sup.+2, stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays wherein the stimulation is inhibited by lactose or thiogalactoside, has an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of FIG. 1 or the relevant portions thereof. The composition is used for treatment of autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, as well as modulating the immune response in an allergic reactions or to organ or tissue transplant rejection. The inventive composition can be combined with general immunosuppressants.

Claims8

Dependent claims

A method to prepare a pharmaceutical composition comprising a

(a) human HL-60 lectin in purified and isolated form, said lectin having an amino acid sequence consisting of positions 2-135 in FIG. 1 including a glycosylation site within positions 96-98, wherein said lectin binds beta-galactoside-containing moieties independent of the presence or absence or Ca.sup.+2, and has a molecular weight of about 14 Kd;
and wherein said lectin is homogenous using the criterion of producing a single peak when subjected to C4-HPLC, is capable of binding to asialofetuin and lypsinized rabbit erythrocytes and wherein agglutination of said lectin is inhibited by thiodigalactoside and beta-lactose;
and
(b) a carbohydrate;
in admixture with at least one pharmaceutically acceptable excipient,
which method comprises lyophilizing said soluble lectin in an aqueous solution containing about 1-40% concentration wt./volume of a protective carbohydrate at a pH of about 4-8.

3 more elements

Dependencies are inferred from the claim text.

Facts

Application

08/719,551Filed 25 Sep 1996 · division

Priority

14 Apr 1988

Granted

20 Jan 1998

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

A61K 38/1709
From vertebrates: from mammals
A61K 38/168
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from plants
A61K 39/395
Medicinal preparations containing antigens or antibodies: antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 47/6415
Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is…:…

Family

Serial181,747Parent of this continuation-in-part · filed 14 Apr 1988

Serial263,734Parent of this continuation-in-part · filed 28 Oct 1988

Serial313,649Parent of this continuation-in-part · filed 21 Feb 1989

Serial976,928Parent of this continuation · filed 16 Nov 1992

Serial326,739Parent of this division · filed 20 Oct 1994

US 5,710,257 AThis patent

From the US filing history. Foreign family members aren’t listed.

Method of causing selective immunosuppression using HL-60-related lectins

Life of this patent

Method of causing selective immunosuppression using HL-60-related lectins

Life of this patent

Abstract

Claims8